Certolizumab pegol for the treatment of psoriasis

被引：20

作者：

Campanati, A. ^{[1
]}

Benfaremo, D. ^{[2
]}

Luchetti, M. M. ^{[2
]}

Ganzetti, G. ^{[1
]}

Gabrielli, A. ^{[2
]}

Offidani, A. ^{[1
]}

机构：

[1] Polytechn Marche Univ, Dept Clin & Mol Sci, Dermatol Clin, Ancona, Italy

[2] Polytechn Marche Univ, Internal Med, Dept Clin & Mol Sci, Via Conca 70, I-60020 Ancona, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2017年 / 17卷 / 03期

关键词：

Certolizumab pegol; psoriasis; psoriatic arthritis; TNF alpha inhibitor; DOUBLE-BLIND; PHASE-III; CLINICAL-RESPONSE; BIOLOGIC THERAPY; CONTROLLED-TRIAL; ALPHA THERAPY; ARTHRITIS; MODERATE; IMMUNOGENICITY; MAINTENANCE;

D O I：

10.1080/14712598.2017.1283401

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: Psoriasis is a chronic immunomediated and inflammatory disease involving mainly skin and joints, often associated with several metabolic and non-metabolic comorbidities. TNF-alpha inhibitors have shown long-term efficacy and safety/tolerability in psoriasis, and preliminary data support the use of certolizumab pegol (CZP) as well.Areas covered: The authors review the pharmacological properties of CZP, as well as its safety data and efficacy profile. They also review the quality of life outcomes related to CZP in psoriasis. The authors also provide their expert opinion on the subject.Expert opinion: CZP is a promising treatment for psoriasis owing to its rapid reduction of disease activity, long-term therapeutic efficacy - both in bio-naive and non-bio-naive patients, long term safety and low rate of site injection reactions. CZP seems to be a promising therapeutic option for psoriasis patients, although further evidence supporting the continuing clinical program for development of CZP in psoriasis is needed.

引用

页码：387 / 394

页数：8

共 50 条

[41] Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study [J].

Gehin, Johanna Elin ;

Goll, Guro Lovik ;

Warren, David John ;

Syversen, Silje Watterdal ;

Sexton, Joseph ;

Strand, Eldri Kveine ;

Kvien, Tore Kristian ;

Bolstad, Nils ;

Lie, Elisabeth .

ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)

[42] Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol [J].

Clowse, Megan E. B. ;

Wolf, Douglas C. ;

Foerger, Frauke ;

Cush, John J. ;

Golembesky, Amanda ;

Shaughnessy, Laura ;

De Cuyper, Dirk ;

Mahadevan, Uma .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (12) :2270-2278

[43] Certolizumab pegol therapy of rheumatoid arthritis: Overview [J].

Zidi, Ines ;

Mnif, Wissem ;

Bouaziz, Aicha ;

Ben Amor, Nidhal .

DRUG DEVELOPMENT RESEARCH, 2011, 72 (07) :603-614

[44] Certolizumab pegol in axial spondyloarthritis [J].

Song, In-Ho ;

Rudwaleit, Martin .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (12) :1161-1172

[45] Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study [J].

Korge, Bernhard ;

Vanhooteghem, Olivier ;

Lynde, Charles W. ;

Machovcova, Alena ;

Perrussel, Marc ;

Lazaridou, Elisavet ;

Marasca, Claudio ;

Sarro, David Vidal ;

Pousa, Ines Duenas ;

Fierens, Frederik ;

Williams, Paulette ;

Shimizu, Saori ;

Heidbrede, Tanja ;

Warren, Richard B. .

DERMATOLOGY AND THERAPY, 2024, 14 (08) :2077-2092

[46] Certolizumab pegol in treatment of Crohn's disease with perianal lesions [J].

Khalif, I. L. ;

Nanaeva, B. A. ;

Shapina, M., V ;

Vardanyan, A. V. .

TERAPEVTICHESKII ARKHIV, 2018, 90 (04) :50-54

[47] Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy [J].

Imafuku, Shinichi ;

Tada, Yayoi ;

Umezawa, Yoshinori ;

Sakurai, Shinya ;

Hoshii, Naoki ;

Nakagawa, Hidemi .

DERMATOLOGY AND THERAPY, 2022, 12 (01) :121-135

[48] Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol [J].

Barnes, Theresa ;

Moots, Robert .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2007, 2 (01) :3-7

[49] Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials [J].

Gottlieb, A. B. ;

Thaci, D. ;

Leonardi, C. ;

Poulin, Y. ;

Kavanagh, S. ;

Boehnlein, M. ;

Reich, K. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 :54-54

[50] Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland [J].

Kumar, Namita ;

Naz, Sophia ;

Quinn, Mark ;

Ryan, John ;

Kumke, Thomas ;

Sheeran, Tom .

ADVANCES IN THERAPY, 2018, 35 (09) :1426-1437

← 1 2 3 4 5 →